cemacabtagene ansegedleucel
cemacabtagene ansegedleucel: developed by 1 company · 3 clinical trials tracked.
cemacabtagene ansegedleucel evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could cemacabtagene ansegedleucel → ALLO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Allogene Therapeutics, Inc. (ALLO) Large B-cell Lymphoma | Phase 3 |
Clinical Trials (3)
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
Primary endpoint: Event-free survival per independent review committee assessment
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Primary endpoint: Progression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review Committee
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Primary endpoint: Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501A
Frequently asked questions
Who is developing cemacabtagene ansegedleucel?
cemacabtagene ansegedleucel is being developed by Allogene Therapeutics, Inc..
How many clinical trials involve cemacabtagene ansegedleucel?
BioSniper tracks 3 clinical trials involving cemacabtagene ansegedleucel.